1. Tansey B. Huge penalty in drug fraud: Pfizer settles felony case in Neurontin off-label promotion. San Francisco Chronicle. 2004 May 14.

2. Harris G. Pfi zer to pay $430 million over promoting drug to doctors. New York Times. 2004 May 14.

3. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ. 2004; 328: 1217.

4. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.

5. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

6. Petersen M. Suit says company promoted drug in exam rooms. New York Times. 2002 May 15.

7. Landefeld C.S., Steinman M.A. The Neurontin legacy – marketing through misinformation and manipulation. N Engl J Med. 2009; 360: 103–6.

8. Petersen M. Court papers suggest scale of drug’s use. New York Times. 2003 May 30.

9. Dickersin K. Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain. Available online at: www.pharmalot.com/wp-content/uploads/2008/10/neurontin-dickersin-2.pdf (accessed 10 December 2008).

10. Saul S. Experts conclude Pfizer manipulated studies. New York Times. 2008 Oct 8.

11. Johansen H.K., Gøtzsche P.C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.

12. Johansen H.K., Gøtzsche P.C. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.

13. Krumholz S.D., Egilman D.S., Ross J.S. Study of Neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. Arch Intern Med. 2011; 171: 1100–7.

14. Adams C., Young A. Off-label prescription case reflects federal concern over unsafe uses. Knight Ridder Newspapers. 2004 May 14.

15. Voris B., Lawrence J. Pfizer Told to Pay $1421. million for Neurontin Fraud. Bloomberg. 2010 March 25.